BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


SEARCH JOBS



About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at http://www.alkermes.com.

Key Executives
Richard F. Pops
Chairman and Chief Executive Officer

Shane Cooke
President

Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer

Mark Stejbach
Senior Vice President, Chief Commercial Officer

Georgianna Harris
Vice President, Regulatory Affairs

Madeline D. Coffin
Vice President, Human Resources

Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer

James M. Frates
Senior Vice President, Chief Financial Officer

Blair C. Jackson
Vice President, Business Development

Michael J. Landine
Senior Vice President, Corporate Development

Rebecca J. Peterson
Senior Vice President, Corporate Communications

Gordon G. Pugh
Senior Vice President, Chief Operating Officer and Chief Risk Officer

Peter Norman
Vice President, Government Affairs and Policy

Srdjan Stankovic
Senior Vice President, Clinical Development and Medical Affairs

Locations

Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642


 Key Statistics


Email: mediainfo@alkermes.com
Ownership:

Web Site: Alkermes plc
Employees: 1,200
Symbol: ALKS
 




Segment
Drug Delivery





 Company News
Alkermes plc (ALKS) To Host Conference Call To Discuss Second Quarter 2014 Financial Results 7/25/2014 9:14:38 AM
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 7/17/2014 10:25:54 AM
Alkermes plc (ALKS) Announces Notices of Allowance For U.S. Patents For Four CNS Pipeline Candidates 7/9/2014 11:18:27 AM
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/18/2014 7:21:16 AM
Alkermes plc (ALKS) Announces Initiation Of FORWARD-3 And FORWARD-4 Efficacy Studies In Pivotal Program For ALKS 5461 For Treatment Of Major Depressive Disorder 6/10/2014 9:50:03 AM
Alkermes plc (ALKS) Files Trademark Infringement Suit Against Boston-Based Biotech Startup Alkeus Pharmaceuticals 6/6/2014 6:57:21 AM
Alkermes plc (ALKS) To Present Data On New Medicines In Development For Schizophrenia And Depression At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 6/3/2014 6:57:19 AM
Alkermes plc (ALKS) Announces Initiation Of Second Phase 2 Clinical Study Of ALKS 3831, A Novel Broad-Spectrum Oral Antipsychotic 6/2/2014 9:04:40 AM
Alkermes plc (ALKS)’ Corporate Presentation To Be Webcast At Two Upcoming Conferences 5/28/2014 7:13:08 AM
Boston CEO Conference To Feature Ceos Of Aegerion Pharmaceuticals, Inc. (AEGR), Alkermes plc (ALKS), Alnylam Pharmaceuticals (ALNY), Flex Pharma, Genzyme Corporation (GENZ), Infinity Pharmaceuticals Inc. (INFI), OvaScience (OVAS), Sarepta Therapeutics (SRPT), Tesaro, Inc. (TSRO), Verastem, Inc. (VSTM) And Others June 4th And 5th 5/20/2014 7:03:42 AM
12345678910...